Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Efficacy and Safety of Oral Bosentan on Healing/Prevention of Digital (Finger) Ulcers in Patients With Scleroderma (RAPIDS-2)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00077584
Recruitment Status : Completed
First Posted : February 11, 2004
Last Update Posted : October 27, 2016
Information provided by (Responsible Party):

Brief Summary:
In an earlier clinical trial, RAPIDS-1, conducted in scleroderma patients with or without digital ulcers at baseline, bosentan significantly reduced the number of new digital ulcers versus placebo. The purpose of the present trial (RAPIDS-2) is to evaluate the prevention and healing effects of bosentan versus placebo on digital ulcers over a 24-week treatment period.

Condition or disease Intervention/treatment Phase
Digital Ulcers Systemic Sclerosis Drug: Bosentan 62.5 mg Drug: Bosentan 125 mg Drug: Placebo Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 188 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double-blind, Placebo-controlled, Multi-center Study to Assess the Effect of Bosentan on Healing and Prevention of Ischemic Digital Ulcers in Patients With Systemic Sclerosis
Study Start Date : October 2003
Actual Primary Completion Date : March 2005
Actual Study Completion Date : May 2005

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Scleroderma
Drug Information available for: Bosentan

Arm Intervention/treatment
Experimental: Bosentan
The patients received bosentan 62.5 mg twice daily (b.i.d.) for 4 weeks and then 125 mg b.i.d. for 20 weeks
Drug: Bosentan 62.5 mg
Oral tablets containing 62.5 mg of bosentan
Other Name: Ro 47-0203

Drug: Bosentan 125 mg
Oral tablets containing 125 mg of bosentan
Other Name: Ro 47-0203

Placebo Comparator: Placebo
The patients received the matching placebo for 24 weeks
Drug: Placebo
Oral tablets matching bosentan 62.5-mg tablets and bosentan 125-mg tablets

Primary Outcome Measures :
  1. Time to complete healing of the cardinal ulcer (CU) up to Week 24 in patients with CU healing maintained for 12 weeks [ Time Frame: 24 weeks ]
  2. Total number of new digital ulcers per patient up to Week 24 [ Time Frame: 24 weeks ]

Secondary Outcome Measures :
  1. Change from baseline to Week 24 in hand pain [ Time Frame: Baseline and Week 24 ]
    Pain assessed on visual analog scales

  2. Change from baseline to Week 24 in hand disability [ Time Frame: Baseline and Week 24 ]
    Hand disability indexed assessed using the Health Assessment Questionaire (HAQ)

  3. Proportion of subjects with treatment-emergent adverse events [ Time Frame: up to 32 weeks (8 week post-treatment follow-up) ]
  4. Proportion of subjects with liver function abnormalities [ Time Frame: Every 4 weeks up to Week 24 ]
    Increase in aminotransferases

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Main Inclusion Criteria:

  • Systemic Sclerosis (SSc), diffuse or limited.
  • SSc patients with at least one digital ulcer at baseline qualifying as a cardinal ulcer.

Main Exclusion Criteria:

  • Digital ulcers due to conditions other than SSc.
  • Severe pulmonary arterial hypertension (PAH) (Who class III and IV).
  • Malabsorption or any severe organ failure (e.g., lung, kidney, liver) or any life-threatening condition.
  • Treatment with parenteral prostanoids (prostaglandin E, epoprostenol, or prostacyclin analogs) during the past 3 months prior to randomization.
  • Treatment with inhaled or oral prostanoids one month prior to randomization.
  • Previous treatment with bosentan.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00077584

Show Show 25 study locations
Sponsors and Collaborators
Layout table for investigator information
Principal Investigator: James Seibold, MD Robert Wood Johnson Medical School, New Brunswick, NJ, USA
Publications of Results:
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Actelion Identifier: NCT00077584    
Obsolete Identifiers: NCT02800993
Other Study ID Numbers: AC-052-331
First Posted: February 11, 2004    Key Record Dates
Last Update Posted: October 27, 2016
Last Verified: October 2016
Keywords provided by Actelion:
Finger Ulcers
Digital Ulcers
Systemic Sclerosis
Additional relevant MeSH terms:
Layout table for MeSH terms
Scleroderma, Systemic
Scleroderma, Diffuse
Skin Ulcer
Pathologic Processes
Connective Tissue Diseases
Skin Diseases
Antihypertensive Agents
Endothelin Receptor Antagonists
Molecular Mechanisms of Pharmacological Action